CureVac NV
CVAC
查看详细走势图
4.300USD
-0.010-0.23%
收盘 12/26, 16:00（美东）报价延迟15分钟
968.24M总市值
8.85市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-0.23%
5天
+3.37%
1月
-21.53%
6月
-20.37%
今年开始到现在
+26.10%
1年
+35.65%
查看详细走势图
TradingKey CureVac NV股票评分
单位: USD 更新时间: 2025-12-26操作建议
CureVac NV当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名61/404位。机构持股占比非常高，近一月多位分析师给出公司评级为持有。最高目标价4.68。中期看，股价处于下降通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
CureVac NV评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
5
位分析师
持有
评级
4.684
目标均价
-10.10%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
CureVac NV亮点
亮点风险
CureVac NV, formerly CureVac AG, is a Germany-based clinical-stage biopharmaceutical company. The Company develops transformative medicines based on messenger ribonucleic acid, or mRNA. The Company's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The Company's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
业绩高增长
公司营业收入稳步增长，连续3年增长380.03%
业绩转盈
公司业绩转盈，最新年度盈利美元
估值高估
公司最新PE估值8.85，处于3年历史高位
机构加仓
最新机构持股23.52M股，环比增加0.19%
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓，最新持仓市值21.87K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.28
CureVac NV新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
CureVac NV简介
CureVac NV, formerly CureVac AG, is a Germany-based clinical-stage biopharmaceutical company. The Company develops transformative medicines based on messenger ribonucleic acid, or mRNA. The Company's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The Company's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
公司代码CVAC
公司CureVac NV
CEOZehnder (Alexander)
网址https://www.curevac.com/
常见问题
CureVac NV(CVAC)的当前股价是多少？
CureVac NV(CVAC)的当前股价是 4.300。
CureVac NV的股票代码是什么？
CureVac NV的股票代码是CVAC。
CureVac NV股票的52周最高点是多少？
CureVac NV股票的52周最高点是5.720。
CureVac NV股票的52周最低点是多少？
CureVac NV股票的52周最低点是2.475。
CureVac NV的市值是多少？
CureVac NV的市值是968.24M。
CureVac NV的净利润是多少？
CureVac NV的净利润为162.19M。
现在CureVac NV(CVAC)的股票是买入、持有还是卖出？
根据分析师评级，CureVac NV(CVAC)的总体评级为持有，目标价格为4.684。
CureVac NV(CVAC)股票的每股收益（EPS TTM）是多少
CureVac NV(CVAC)股票的每股收益（EPS TTM）是0.486。
相关品种
